Neuralink Raises $650M at $9B Valuation
Analysis based on 8 articles · First reported May 27, 2025 · Last updated Jun 03, 2025
The successful $650 million funding round for Neuralink, valuing it at $9 billion, signals strong investor confidence in brain-computer interface technology. This event could lead to increased investment and innovation in the medical device and biotechnology sectors, potentially impacting publicly traded companies in these industries as well.
Neuralink, founded by Elon Musk, has successfully closed a Series E funding round, raising $650 million. This latest investment values the private company at $9 billion pre-money. Key investors in this round include ARK Investment Management, Italian Founders Fund, Sequoia Capital, and Thrive Capital. The funding will be used to accelerate Neuralink's clinical trials and further develop its brain-computer interface technology. The United States — Food and Drug Administration has granted Neuralink 'breakthrough device' designation, which expedites the development and review process for its implants. Neuralink has already conducted human clinical trials, implanting its brain chips in five individuals with severe paralysis, enabling them to control digital devices with their thoughts. The company aims to expand patient access and develop next-generation devices for a 'whole-brain interface'.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard